Suspected DLIS interference in the dimension DGNA digoxin assay method and the clinical application of the revised digoxin target range

Therapeutic Drug Monitoring

Volumn 28, Issue 3, 2006, Pages 454-457

  Morris, Raymond G ^a,b   Jones, Terry E ^a   Goldsworthy, Sharon J ^a   Wagner, Tasma J ^a   Ho, Helen ^a   Horowitz, John D ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Digoxin; DLIS; Immunoassay; Therapeutic drug monitoring

Indexed keywords

DIGITALIS LIKE FACTOR; DIGOXIN; FUROSEMIDE; GLICLAZIDE; IRBESARTAN; ISOSORBIDE DINITRATE;

AGED; ARTICLE; CASE REPORT; CLINICAL MEDICINE; CLINICAL PHARMACOLOGY; DOSE CALCULATION; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXPOSURE; DRUG MONITORING; DRUG TARGETING; FEMALE; HEART FAILURE; HUMAN; IMMUNOASSAY; KIDNEY DYSFUNCTION; LABORATORY APPARATUS, EQUIPMENT AND SUPPLIES; LABORATORY TEST; LONG TERM CARE; MOLECULAR WEIGHT; PLASMA; PRIORITY JOURNAL; SAMPLE; ULTRAFILTRATION;

AGED; CARDENOLIDES; CARDIOTONIC AGENTS; DIGOXIN; DRUG MONITORING; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOASSAY; SAPONINS;

EID: 33748193711     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ftd.0000211818.35182.cb     Document Type: Article

References (26)

1. Gruber KA, Whitaker JM, Buckalew VM. Endogenous digitalis-like substance in plasma of volume-expanded dogs. Nature. 1980;287:743-745.
2. Jortani SA, Valdes R. Digoxin and its related endogenous factors. Crit Rev Clin Lab Sci. 1997;34:225-274.
3. Morris RG, Frewin DB, Saccoia NC, et al. Interference from digoxin-like immunoreactive substance(s) in commercial digoxin kit methods. Eur J Clin Pharmacol. 1990;39:359-363.
4. Shilo L, Adawi A, Solomon G, et al. Endogenous digoxin-like immunoreactivity in congestive heart failure. Br Med J. 1987;295:415-416.
5. Valdes R. Endogenous digoxin-like immunoreactive factor in human subjects. Fed Proc. 1985;44:2800-2805.
6. registered IMS™ 800i system is virtually free from interference of endogenous digoxin-like immunoreactive factors. Ther Drug Monit. 2005;27:139-143.
7. Hayashi T, Ijiri Y, Toko H, et al. Increased digitalis-like immunoreactive substances in patients with hypertrophic cardiomyopathy. Eur Heart J. 2000;4:296-305.
8. Sang-Ling W, Li W, Wells A, et al. Digoxin-like and digitoxin-like immunoreactive substances in elderly people: Impact on therapeutic drug monitoring of digoxin and digitoxin concentrations. Am J Clin Pathol. 2001;115:600-604.
9. Straub RH, Hall C, Kramer BK, et al. Atrial natriuretic factor and digoxin-like immunoreactive factor in diabetic patients: Their interrelation and the influence of the autonomic nervous system. J Clin Endocrinol Metab. 1996;81:3385-3389.
10. Rathore SS, Curtis JP, Wang Y, et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA. 2003;289:871-878.
11. Morris RG, Frewin DB, Taylor WB, et al. The effect of renal and hepatic impairment and of spironolactone on digoxin assays. Eur J Clin Pharmacol. 1988;34:233-240.
12. Steimer W, Muller C, Eber B. Digoxin assays: Frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin Chem. 2002;48:507-516.
13. Dasgupta A, Wu S, Olsen M, et al. Effect of Asian and Siberian ginseng on serum digoxin measurement by five immunoassays: significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol. 2003;119:298-303.
14. Konishi H, Shimizu S, Chiba M, et al. Predictive performance of serum digoxin concentration in patients with congestive heart failure by a hyperbolic model based on creatinine clearance. J Clin Pharm Ther. 2002;27:257-265.
15. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
16. Morris RG, Frewin DB, Saccoia NC, et al. Digoxin-like immunoreactive substance levels in cord blood obtained from twins. Eur J Clin Pharmacol. 1991;40:199-200.
17. Dimension® clinical chemistry system. Flex® reagent cartridge DGNA. Ref DF35A. Dade Behring Inc, Newark, DE USA, 2000.
18. Stone JA, Soldin SJ. Update of digoxin. Clin Chem. 1989;35:1326-1331.
19. Dasgupta A, Trejo O. Suppression of total digoxin concentrations by digoxin-like immunoreactive substances in the MEIA digoxin assay; elimination of negative interference by monitoring free digoxin concentration. Am J Clin Pathol. 1999;111:406-410.
20. Dasgupta A, Saldana S, Heimann P. Monitoring free digoxin instead of total digoxin in patients with congestive heart failure and high concentrations of digoxin like immunoreactive substances. Clin Chem. 1990;36:2121-2123.
21. Rowland M, Tozer TN. Clinical Pharmacokinetics - Concepts and Applications. Philadelphia, PA: Lea & Febiger; 1980.
22. Friedman HS, Babb B, Shim IB, et al. Demonstration of a relationship between urinary digoxin-like immunoreactive substance and cardiac performance. Chest. 1993;103:878-881.
23. Shah VP, Midha KK, Findlay JWA, et al. Bioanalytical method validation. A revisit with a decade of progress. Pharm Res. 2000;17:1551-1557.
24. Abad-Santos F, Carcas AJ, Ibanez C, et al. Digoxin level and clinical manifestations as determinants in the diagnosis of digoxin toxicity. Ther Drug Monit. 2000;22:163-168.
25. Biopharmaceutics Coordinating Committee Center for Drug Evaluation and Research (CDER). Guidance for Industry: Bioanalytical Method Validation. Washington:US Department of Health and Human Services, FDA; May 2001.
26. Qazzaz HMAM, Valdes R. Simultaneous isolation of endogenous digoxin-like immunoreactive factor, oubain-like factor, and deglycosylated congeners from mammalian tissues. Arch Biochem Biophys. 1996;328:193-200.